These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 9272607)

  • 1. The postprandial state and the risk of atherosclerosis.
    Hanefeld M; Temelkova-Kurktschiev T
    Diabet Med; 1997 Aug; 14 Suppl 3():S6-11. PubMed ID: 9272607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired glucose tolerance is not associated with lipid intolerance.
    Henkel E; Temelkova-Kurktschiev T; Koehler C; Pietzsch J; Leonhardt W; Hanefeld M
    Diabetes Nutr Metab; 2002 Apr; 15(2):84-90. PubMed ID: 12059096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.
    Henkel E; Menschikowski M; Koehler C; Leonhardt W; Hanefeld M
    Metabolism; 2005 Sep; 54(9):1168-73. PubMed ID: 16125528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should postprandial hyperglycaemia in prediabetic and type 2 diabetic patients be treated?
    Charpentier G; Riveline JP; Dardari D; Varroud-Vial M
    Drugs; 2006; 66(3):273-86. PubMed ID: 16526817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of future diabetes is as high with abnormal intermediate post-glucose response as with impaired glucose tolerance.
    Viswanathan V; Clementina M; Nair BM; Satyavani K
    J Assoc Physicians India; 2007 Dec; 55():833-7. PubMed ID: 18405128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated 1-h post-load plasma glucose levels in subjects with normal glucose tolerance are associated with a pro-atherogenic lipid profile.
    Andreozzi F; Mannino GC; Perticone M; Perticone F; Sesti G
    Atherosclerosis; 2017 Jan; 256():15-20. PubMed ID: 27940375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of genetic prediabetic south Indian subjects. Importance of hyperinsulinemia and beta-cell dysfunction.
    Snehalatha C; Ramachandran A; Satyavani K; Latha E; Viswanathan V
    Diabetes Care; 1998 Jan; 21(1):76-9. PubMed ID: 9538973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance.
    Bock G; Dalla Man C; Campioni M; Chittilapilly E; Basu R; Toffolo G; Cobelli C; Rizza R
    Diabetes; 2006 Dec; 55(12):3536-49. PubMed ID: 17130502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Postprandial blood glucose as the driving force in pathogenesis of type 2 diabetes].
    Liebl A
    Med Klin (Munich); 2003 Oct; 98 Suppl 1():7-11. PubMed ID: 14694835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postprandial lipaemia in patients with impaired fasting glucose, impaired glucose tolerance and diabetes mellitus.
    Madhu SV; Kant S; Srivastava S; Kant R; Sharma SB; Bhadoria DP
    Diabetes Res Clin Pract; 2008 Jun; 80(3):380-5. PubMed ID: 18321605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The postprandial state: mechanisms of glucose intolerance.
    Dinneen SF
    Diabet Med; 1997 Aug; 14 Suppl 3():S19-24. PubMed ID: 9272609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.
    Kirkman MS; Shankar RR; Shankar S; Shen C; Brizendine E; Baron A; McGill J
    Diabetes Care; 2006 Sep; 29(9):2095-101. PubMed ID: 16936159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Characteristics of glycemic excursion in different subtypes of impaired glucose intolerance].
    Kang Y; Lu JM; Sun JF; Li CL; Wang XL; Zhang XQ; Lü ZH; Dou JT; Mu YM
    Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(10):669-72. PubMed ID: 19595059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new approach for investigating the relative contribution of basal glucose and postprandial glucose to HbA1
    Ma J; He H; Yang X; Chen D; Tan C; Zhong L; Du Q; Wu X; Gao Y; Liu G; Wang C; Ran X
    Nutr Diabetes; 2021 Jun; 11(1):14. PubMed ID: 34088897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postprandial hyperglycaemia: noxious effects on the vessel wall.
    Hanefeld M
    Int J Clin Pract Suppl; 2002 Jul; (129):45-50. PubMed ID: 12166606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperproinsulinemia of type II diabetes is not present before the development of hyperglycemia.
    Birkeland KI; Torjesen PA; Eriksson J; Vaaler S; Groop L
    Diabetes Care; 1994 Nov; 17(11):1307-10. PubMed ID: 7821172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transient impaired glucose tolerance in South African Indians does not carry a risk for progression to NIDDM.
    Motala AA; Omar MA; Gouws E
    Diabetes Care; 1997 Jul; 20(7):1101-7. PubMed ID: 9203444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
    Sakamoto N; Tajima N
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421
    [No Abstract]   [Full Text] [Related]  

  • 20. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
    Chiasson JL; Gomis R; Hanefeld M; Josse RG; Karasik A; Laakso M
    Diabetes Care; 1998 Oct; 21(10):1720-5. PubMed ID: 9773737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.